Response to Jia and Wang.
作者信息
Liu Xu, Liu Qi, Yao Xueting, Zhang Miao, Cui Cheng, Li Haiyan, Liu Dongyang
机构信息
Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China.
出版信息
Clin Infect Dis. 2021 Jul 15;73(2):352-353. doi: 10.1093/cid/ciaa1390.
Abstract
摘要
相似文献
1
Response to Jia and Wang.对贾和王的回应。
Clin Infect Dis. 2021 Jul 15;73(2):352-353. doi: 10.1093/cid/ciaa1390.
2
Methotrexate for juvenile idiopathic arthritis.甲氨蝶呤用于青少年特发性关节炎。
Cochrane Database Syst Rev. 2024 Feb 9;2(2):CD003129. doi: 10.1002/14651858.CD003129.pub2.
3
The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.阿巴西普、阿达木单抗、依那西普和托珠单抗治疗幼年特发性关节炎的临床有效性和成本效益：一项系统评价和经济学评估
Health Technol Assess. 2016 Apr;20(34):1-222. doi: 10.3310/hta20340.
4
Increased methotrexate intolerance in juvenile idiopathic arthritis compared to acute lymphoblastic leukaemia in children.与儿童急性淋巴细胞白血病相比，幼年特发性关节炎患儿对甲氨蝶呤不耐受的发生率增加。
PLoS One. 2019 Jul 11;14(7):e0219539. doi: 10.1371/journal.pone.0219539. eCollection 2019.
5
Recommendations for the use of methotrexate in juvenile idiopathic arthritis.甲氨蝶呤在幼年特发性关节炎中的使用建议。
Paediatr Drugs. 2006;8(6):347-56. doi: 10.2165/00148581-200608060-00003.
6
Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.阿达木单抗联合甲氨蝶呤治疗与幼年特发性关节炎相关的难治性葡萄膜炎：一项 RCT。
Health Technol Assess. 2019 Apr;23(15):1-140. doi: 10.3310/hta23150.
7
Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.甲氨蝶呤用于青少年特发性关节炎：MARAJIA专家共识会议的建议与推荐
Pediatr Rheumatol Online J. 2018 Jul 11;16(1):46. doi: 10.1186/s12969-018-0255-8.
8
A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.比较用于评估接受甲氨蝶呤和/或抗肿瘤坏死因子α药物治疗的幼年特发性关节炎患者治疗反应的反应标准。
Arthritis Rheum. 2006 May;54(5):1602-7. doi: 10.1002/art.21784.
9
Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate.对甲氨蝶呤治疗反应不佳的幼年特发性关节炎患者血液的转录谱。
Rheumatology (Oxford). 2017 Sep 1;56(9):1542-1551. doi: 10.1093/rheumatology/kex206.
10
A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).阿达木单抗联合甲氨蝶呤治疗青少年特发性关节炎相关性葡萄膜炎的临床疗效、安全性及成本效益的随机对照试验（SYCAMORE试验）
Trials. 2014 Jan 9;15:14. doi: 10.1186/1745-6215-15-14.
本文引用的文献
1
Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19.一项关于氯喹治疗COVID-19安全性和有效性的多中心前瞻性观察性研究的初步证据。
Natl Sci Rev. 2020 May 28;7(9):1428-1436. doi: 10.1093/nsr/nwaa113. eCollection 2020 Sep.
2
How Could In Vitro Antiviral Activity Be Applied to Optimize the Dosing Regimens of Candidates for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)?如何将体外抗病毒活性应用于优化严重急性呼吸综合征冠状病毒2（SARS-CoV-2）治疗候选药物的给药方案？
Clin Infect Dis. 2021 Jul 15;73(2):352-353. doi: 10.1093/cid/ciaa1325.
3
Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.氯喹与洛匹那韦/利托那韦治疗轻症/普通 COVID-19 感染的疗效：一项前瞻性、开放标签、多中心、随机对照临床研究。
Trials. 2020 Jul 8;21(1):622. doi: 10.1186/s13063-020-04478-w.
4
Does In Vitro Potency Predict Clinically Efficacious Concentrations?体外效力能否预测临床有效浓度？
Clin Pharmacol Ther. 2020 Aug;108(2):298-305. doi: 10.1002/cpt.1846. Epub 2020 May 10.
5
Treating COVID-19 with Chloroquine.用氯喹治疗新型冠状病毒肺炎。
J Mol Cell Biol. 2020 May 18;12(4):322-325. doi: 10.1093/jmcb/mjaa014.
6
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
Zotero 插件